# SomaLogic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/somalogic

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.somalogic.com/
- Total disclosed funding: $469M
- Latest round: Series A (Jan 5, 2021)
- Investors on record: 35

## About

SomaLogic, Inc., based in the US, is a clinical proteomics company focused on advanced protein measurement technologies to support healthcare and life sciences applications. SomaLogic, Inc. specializes in proteomics, providing innovative assays for protein analysis. Founded in 2000 by Larry Gold and David Brunel, and headquartered in Boulder, Colorado. In June 2025, Illumina, Inc. acquired SomaLogic, Inc. from Standard BioTools Inc., Casdin Capital and Viking Global Investors for USD 350 million in cash. The company was founded by Alicia Hodnefield and is led by CEO Roy Smythe. SomaLogic Operating Co., Inc. offers the SomaScan Assay Services, a proprietary proteomics platform capable of measuring 11,000 proteins from just 55-µL of sample. Utilized in a CLIA-certified and CAP-accredited lab, the platform serves clients across North America, Europe, and Asia-Pacific, including academic medical centers and pharmaceutical companies, facilitating high-throughput protein profiling for various applications in health and disease research. SomaLogic generates revenue through proteomics assay services, licensing of its SomaScan® technology, and collaborations with pharmaceutical and biotech companies. It also earns from product sales of its SOMAmer reagents and contract research services. Following its acquisition by Illumina in June 2025, SomaLogic is positioned to play a central role in advancing multiomics by integrating its proteomics technology with Illumina’s next-generation sequencing (NGS) platforms. The combined capabilities aim to reduce the cost and time of proteomic research, expand into clinical diagnostics, and accelerate biomarker discovery.

## Funding rounds

- Series A, Jan 5, 2021, $109M — Boston Millennia Partners, T Rowe Price, Novartis Venture Fund, NEC, Millennium Management, Foresite Capital, Redmile Group, Casdin Capital, Farallon Capital Management, Monashee Investment Management, Revelation Partners, Qstar Capital, Madryn Asset Management, Janus Henderson Investors, Soleus Capital, Blue Water Life Science Fund, Intermountain Ventures, Logos Capital, Ziff Capital Partners, Fiscus Ventures
- Series A, Nov 20, 2020, $103M — T Rowe Price, Foresite Capital, Casdin Capital, Farallon Capital Management, Monashee Investment Management, Qstar Capital, Madryn Asset Management, Soleus Capital, Blue Water Life Science Fund, Mossrock Capital, Fiscus Ventures
- Series A, Jul 13, 2016, $163M — Visium Asset Management
- Series A, Nov 9, 2010, $15M — Akina, SGAM Private Equity, Otsuka Pharmaceutical Co., Ltd., Affentranger Associates, Sumitomo Bakelite Co., Ltd., Skye Investment Advisors
- Series A, Mar 10, 2008, $35M — ProQuest Investments, Quest Diagnostics Incorporated, Otsuka Pharmaceutical Co., Ltd., MorrGold LLC, Stronghold Capital
- Series D, Nov 13, 2003, $5M — Mitsui Global Investment, Sumitomo Bakelite Co., Ltd.
- Series C, Feb 20, 2003, $12M — Mitsui Global Investment
- Series C, Jul 5, 2002, $8M — Mitsui Global Investment
- Series B, Nov 9, 2000, $20M — SGAM Private Equity, NewWest Mezzanine, ProQuest Investments, Lombard Odier Asset Management

## Investors

- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series B, Series A
- NewWest Mezzanine (https://capitalatlas.ai/funds/newwest-mezzanine) — Series B
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B, Series A
- Lombard Odier Asset Management — Series B
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series C, Series D
- Sumitomo Bakelite Co., Ltd. — Series D, Series A
- Quest Diagnostics Incorporated — Series A
- Otsuka Pharmaceutical Co., Ltd. — Series A
- MorrGold LLC — Series A
- Stronghold Capital (https://capitalatlas.ai/funds/stronghold-capital) — Series A
- Akina (https://capitalatlas.ai/funds/akina) — Series A
- Affentranger Associates — Series A
- Skye Investment Advisors — Series A
- Visium Asset Management (https://capitalatlas.ai/funds/visium-asset-management) — Series A
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series A
- Monashee Investment Management — Series A
- Qstar Capital (https://capitalatlas.ai/funds/qstar-capital) — Series A
- Madryn Asset Management (https://capitalatlas.ai/funds/madryn-asset-management) — Series A
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series A
- Blue Water Life Science Fund — Series A
- Mossrock Capital (https://capitalatlas.ai/funds/mossrock-capital) — Series A
- Fiscus Ventures — Series A
- Boston Millennia Partners (https://capitalatlas.ai/funds/boston-millennia-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- NEC — Series A
- Millennium Management — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series A
- Janus Henderson Investors — Series A
- Intermountain Ventures (https://capitalatlas.ai/funds/intermountain-ventures) — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- Ziff Capital Partners — Series A